School of Medicine
Showing 51-100 of 154 Results
-
Fumiaki Ikeno
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
Researcher Cardiovascular Medicine, Stanford University
Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University
Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Contact Information
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406 -
Kathy Johnson
Executive Administrator, SPARK at Stanford
Current Role at StanfordProgram Administrator, SPARK at Stanford
Executive Admin to:
Daria Mochly-Rosen, Professor
Kevin V. Grimes, Professor - Teaching
Department of Chemical & Systems Biology -
Sharada Kalanidhi
Director of Data Science, Biochemistry - Genome Center
Current Role at StanfordParaphrasing the mathematician Alexander Grothendieck: the essential thing is to pose problems in the right framework.
Sharada is developing a new field, Mathematical Medicine, which applies pure mathematical frameworks to genomic and multi-omic data for quantitative, personalized diagnosis. This approach explores alternatives to prevailing cohort-based statistical paradigms, particularly in complex clinical cases that have resisted standard methods.
After more than a decade of research and close collaboration with biochemists at the Stanford Genome Technology Center (Dept. of Biochemistry), Sharada concluded that the mathematics currently used for multi-omic diagnosis is inadequate for the level of biological and clinical complexity being attempted. Her conclusion echoes the perspective of the mathematician Mikhail Gromov: “This area does not yet exist. It will have to be invented.” Mathematical Medicine represents one possible construction of such an area. This approach is aligned in spirit with the philosophy of the late mathematician Jim Simons: "We don't start with models. We start with data. We don't have any preconceived notions." Mathematical Medicine lets the data speak for itself.
This field is focused on the development of an intermediate translation layer between cohort-based statistical models and individualized multi-omic diagnosis and clinical decision-making. Without this mathematical layer, the clinical adoption of multi-omic data- particularly for complex cases- has been limited. As a result, many complex, multi-system conditions remain undiagnosed or misdiagnosed for long periods, delaying effective treatment and, in some cases, allowing disease processes to worsen. Additionally, what is learned from rare and extreme cases proves highly informative for the rest of the population.
Further information on this field, including opportunities for early philanthropic partnerships, is available at: https://mathmed-2026.web.app/ -
Devanish Narasimhasanth Kamtam
Visiting Instructor, Cardiothoracic Surgery - Thoracic Surgery
BioDr. Devanish Kamtam is a Visiting Instructor in the Division of Thoracic Surgery at Stanford University, working in Dr. Joseph Shrager's lab. His research focuses on surgical AI, AI in medical imaging, and clinical outcomes in Thoracic Surgery. He completed his MBBS at Gandhi Medical College, Hyderabad and MS in General Surgery at AIIMS New Delhi.
-
Jeewon Sylvia Kim
Program Manager, SPARK at Stanford
Current Role at StanfordProgram manager for SPARK Translational Science Program overseeing educational seminar series, managing projects and facilitating SPARK global operations.
-
Bruce Koch, Ph.D.
Senior Research Scientist-Basic Life, Sarafan ChEM-H
Current Role at StanfordDirector, ChEM-H/CSB High Throughput Screening Group
Staff Lead, IMA HTS Module
Adviser to the SPARK Program -
Marc Leon (aka Hongliang Liang) MD, PhD
Clinical Assistant Professor, Cardiothoracic Surgery
BioMarc Leon (also known as Hongliang Liang), M.D., Ph.D., previously served as Chief Surgeon, Associate Professor of Cardiovascular Surgery, and Director of the Division of Coronary Artery Surgery at Xijing Hospital in Xi'an, China. Currently, he is a Clinical Assistant Professor in the Department of Cardiothoracic Surgery at Stanford Hospital. Dr. Leon is a surgeon member of the Society of Thoracic Surgeons (STS), the International Society of Heart and Lung Transplantation (ISHLT), and the Chinese American Academy of Cardiology (CAAC). His clinical and research expertise includes the surgical management of cardiopulmonary failure, heart valve disease, and ischemic heart disease, along with the application of stem cell therapy for myocardial infarction. Additionally, Dr. Leon is actively engaged in exploring the application of artificial intelligence in the field of cardiovascular diseases.
-
Joanna E. Liliental, PhD
Director, TRAM, M-TRAM, TASC, Med/TRAM
Current Role at StanfordExecutive Director, Master's in TRAM (M-TRAM)
https://med.stanford.edu/tram/masters-program.html
Director, Translational Applications Service Center (TASC)
http://tasc.stanford.edu
Associate Director, Translational Research and Applied Medicine (TRAM) Program
http://tram.stanford.edu
Senior Research Scientist, Stanford School of Medicine
Instructor of University Courses: MED221,MED121, MED212A
Member, Stanford Cancer Institute -
Xin Liu
Basic Life Science Research Scientist, Genetics
BioXin Liu is a postdoctoral Research Scientist in the Department of Genetics at Stanford University. Xin holds a PhD in Chemistry from the University of Michigan, Ann Arbor. Her basic research interests include RNA and protein biochemistry, enzymology, cancer immunology, and autoimmune disease. She has published papers in several prestigious journals in the field of biochemistry, including Nature Communications, Journal of American Chemical Society, and Nucleic Acids Research. The highlight of her multidisciplinary research includes the development of high-throughput enzymatic methods to discover anti-microbial agents and to reveal mechanisms behind human mitochondrial diseases, as well as innovative applications of genome engineering and machine-learning to decode principles of RNA editing in human cells. Her current research focuses on the mechanistic study of innate immune pathways.
-
Kathryn Melsop
Director, Finance & Facility Operations, Stanford Laboratory for Cell and Gene Medicine
Current Role at StanfordDirector, Finance and Facility Operations at the Laboratory for Cell & Gene Medicine.
-
Antonio Meola, MD, PhD
BioAntonio Meola M.D. Ph.D graduated Summa cum Laude and Research Honors at the University of Pisa, Italy, in 2008, and completed his residency training in Neurosurgery at the same Institution in July 2015. Dr Meola attended a Ph.D. program at the University of Florence, Italy, where he discussed a doctoral thesis entitled "A New Head-Mounted Display-based Augmented Reality System in Neurosurgical Oncology: a study on phantom".
Since 2/2014 to 1/2015 Dr Meola completed a Research Fellowship in Neurosurgical anatomy at the University of Pittsburgh Medical Center (UPMC), under the Direction of Dr. Juan C. Fernandez-Miranda. The main focus of his research was the surgical neuroanatomy of the white matter tracts of the human brain.
Since 7/2015 to 6/2016 Dr Meola served as Clinical Fellow in Image-Guided Neurosurgery at the Brigham and Women's Hospital, Harvard Medical School, in Boston, MA (Director: Dr. Alexandra J. Golby M.D.). During the fellowship, he focused on the clinical application and integration of advanced imaging techniques, including intraoperative-MRI, intraoperative US, functional MRI, tractography.
Since 7/2016 to 6/2017 Dr Meola completed a Neurosurgical Oncology Fellowship at the Cleveland Clinic in Cleveland, OH, devoting his efforts to minimally-invasive neurosurgical techniques, such as Laser interstitial Thermal Therapy (LITT) and stereotactic radiosurgery (Gamma Knife), as well as to awake neurosurgery.
Starting 7/2017, Dr Meola joined the Department of Neurosurgery at Stanford. Dr. Meola mainly focuses on conventional and innovative treatments for brain and skull base tumors, including both surgery and stereotactic radiosurgery (CyberKnife). -
Pardis Miri
Basic Life Research Scientist, Genetics
BioPardis Miri, PhD, is a Research Scientist and former Postdoctoral Fellow at Stanford University, where she develops technology aimed at improving mental well-being. She holds a PhD in Computer Science and has extensive training in affective science under Professor James J. Gross. Pardis leads a multidisciplinary team (http://wehab.stanford.edu
) conducting clinical and real-world studies to assess how wearable technologies can reduce stress and enhance glymphatic flow in early-stage Alzheimer’s patients.
During her postdoctoral work, Pardis served as the principal investigator of FAR, a multi-disciplinary project to design, build, and evaluate an end-to-end wearable system for children with emotion dysregulation, including those diagnosed with autism spectrum disorder. FAR aims to support more adaptive emotion-regulation strategies through a combination of systems design and behavioral research.
Pardis is advised by Professors Michael Snyder, Keith Marzullo, and James J. Gross, and collaborates with Professor Antonio Hardan of the Stanford School of Medicine on research involving children with autism spectrum disorder. -
Dhriti Nagar
Postdoctoral Scholar, Neonatal and Developmental Medicine
BioPremature birth is a leading cause of developmental and neuropsychiatric disorders in children. One of the factors causing these defects is lowered levels of available oxygen (hypoxia) in the newborn due to immature lungs. My research focuses on understanding the cellular and molecular mechanisms underlying hypoxia-induced developmental disorders of the nervous system due to preterm birth.
-
Michitaka Nakano
Basic Life Research Scientist, Medicine - Med/Hematology
BioI am a MD/PhD postdoctoral fellow and medical oncologist with a long-standing interest in translational cancer research. My long-term goal is to be a lab-based physician-scientist and independent academic researcher, translating basic cancer research, and mentoring next-generation scientists. My thesis work in Japan focused on cancer stem cell equilibrium by uniquely applying organoid culture as a method to elucidate cancer stem cell dynamics, which was awarded in Japanese Cancer Association. Along with the development of the field represented by success in T cell checkpoint, my interest gradually shifted to immune oncology while I examined numerous numbers of cancer patients as a medical oncology fellow. My postdoctoral fellowship at Calvin Kuo Lab in Stanford (2019-present) focuses on tumor immune microenvironment. Kuo lab developed a unique 3D air-liquid interface (ALI) organoid system that cultures tumors while preserving their endogenous infiltrating immune cells (T,B ,NK, Myeloid cells). My postdoctoral work will prove the significance of organoids as a translational tool to discover tumor-immune interaction by novel checkpoint inhibitors for immune cells, which can be broadly applicable to basic cancer biology, precision medicine, therapeutics validation and biomarker discovery.
